Carlos Costa
Known title: Chief People OfficerCIK: 0001939167
Associated companies
Transaction History
| FHTX | ▲ Buy | Option Exercise | 857 | $3K | 9/23/2024 | View on chart |
| FHTX | ▼ Sell | Open Market | 857 | $9K | 9/23/2024 | View on chart |
| FHTX | ▲ Buy | Option Exercise | 35,756 | $133K | 9/20/2024 | View on chart |
| FHTX | ▼ Sell | Open Market | 35,756 | $359K | 9/20/2024 | View on chart |
| FHTX | ▲ Buy | Option Exercise | 11,574 | $43K | 9/18/2024 | View on chart |
| FHTX | ▼ Sell | Open Market | 11,574 | $116K | 9/18/2024 | View on chart |
| FHTX | ▼ Sell | Open Market | 10,272 | $103K | 9/17/2024 | View on chart |
| FHTX | ▲ Buy | Option Exercise | 10,272 | $38K | 9/17/2024 | View on chart |
| FHTX | ▲ Buy | Option Exercise | 400 | $1K | 9/16/2024 | View on chart |
| FHTX | ▼ Sell | Open Market | 400 | $4K | 9/16/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Foghorn and Lilly halt FHD-909 development
Foghorn Therapeutics announced it will not advance the FHD-909 program into the clinical development expansion phase with Lilly. This decision marks a significant setback for the company's pipeline, as it halts progress on a key partnership. The news explains why the stock is trading near its 52-week low, reflecting the impact of this strategic pause on market sentiment.
Foghorn and Lilly halt FHD-909 development. Foghorn Therapeutics announced it will not advance the FHD-909 program into the clinical development expansion phase with Lilly. This decision marks a significant setback for the company's pipeline, as it halts progress on a key partnership. The news explains why the stock is trading near its 52-week low, reflecting the impact of this strategic pause on market sentiment.